Last updated: April 26, 2026
Who Supplies CARTIA XT (Diltiazem Hydrochloride Extended-Release) and What’s Known from Public Records?
No complete, reliably citable supplier list for CARTIA XT can be produced from the information available in this chat.
What suppliers are assignable to CARTIA XT?
No supplier dataset, manufacturing/packaging site list, label-holder supply chain disclosure, or patent-family manufacturing attribution for CARTIA XT (diltiazem hydrochloride extended-release) is present here, so a definitive supplier map cannot be generated without risking factual error.
What sourcing categories are typically needed to name “suppliers”?
A correct supplier answer requires at least one of the following, none of which are provided in the input:
- NDA/label-holder supply chain disclosures (e.g., manufacturing sites, packaging sites, responsible parties)
- ANDA and FDA drug-label “Manufactured for/Distributed by” statements tied to the specific strength and dosage form
- Patent family inventorship and assignment tied to manufacturing or process licensors
- DMF-backed API supplier disclosures or FDA-referenced DMFs (API source)
- Commercial procurement disclosures (e.g., audited supplier statements, form 10-K risk factors, procurement exhibits)
- Trade name specific sourcing (CARTIA XT may share upstream supply with other diltiazem ER brands, but the linkage must be proven by label-site statements)
Why a supplier list can’t be completed from this prompt
A “suppliers for CARTIA XT” deliverable is inherently document-specific. Without label text, FDA submission references (NDA/ANDA), DMF numbers, or manufacturing site statements, any named suppliers would be speculative.
Key Takeaways
- A complete supplier list for CARTIA XT requires documented label or regulatory sourcing data tied to the product.
- This chat contains no citable records that identify CARTIA XT manufacturing, packaging, or API suppliers.
- Producing a supplier list without those records would introduce factual risk.
FAQs
-
What counts as a “supplier” for an oral ER drug like CARTIA XT?
API manufacturer, tablet core manufacturer, finished dosage manufacturer, packaging site, and distributor/label holder are typically treated as supplier nodes.
-
Can API and finished-dose suppliers differ for CARTIA XT?
Yes. API sourcing can be separate from finished-dose and packaging, and brand labels often split these roles.
-
Do DMFs determine CARTIA XT’s API supplier list?
DMFs can identify or constrain API suppliers, but only when the relevant DMF references are available and tied to the specific product submission.
-
Where do the most defensible supplier names come from?
FDA-linked label/manufacturing site statements, NDA/ANDA labeling, and submission-linked DMF references.
-
If multiple suppliers exist, how is the final list determined?
By product-specific, time-bounded evidence from label text and regulatory manufacturing/packaging site references.
References (APA)
1.
